|Day Low/High||2.05 / 2.15|
|52 Wk Low/High||1.50 / 4.21|
Total Revenue increased 59% driven by the etailz segment
Total Revenue increased 35% driven by the etailz segment
Annual Total Revenue increased 20% driven by revenue from the recently acquired etailz segment
Provides Financial Flexibility While Lowering Borrowing Costs
These names frequently trade at low multiples to current assets and may (but may not) be worthy of purchase.
Just five non-biotech names trade below net current asset value.
With the S&P 500 at or near record highs, wait for prices to fall.
Reports flat comparable store sales and historically high gross margin for the First Quarter
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.